ADTX

Aditxt, Inc. (NASDAQ:ADTX) is a Richmond, Virginia-based biotechnology company that was incorporated in 2017 and went public in June 2020. Originally known as ADiTx Therapeutics, Inc., the company changed its name to Aditxt, Inc. in July 2021. The company focuses on developing innovative technologies to improve immune system health through immune mapping and reprogramming approaches. Aditxt operates in the highly specialized field of immunotherapy, working on both diagnostic tools and therapeutic interventions that could potentially transform how immune-related conditions are understood and treated.